XtalPi Acquires Liverpool ChiroChem (LCC)

Schrödinger Acquires XTAL BioStructures

January 14, 2022

Biotechnology

Schrödinger, Inc. acquired XTAL BioStructures, Inc., a Natick, Massachusetts–based structural biology services provider, in an all-cash transaction that closed January 14, 2022 for $6 million. The acquisition brings protein production, purification, biophysical methods and X-ray crystallography capabilities in‑house to support Schrödinger's structure-based drug discovery platform and expand its experimental offerings for customers.

Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities

July 9, 2024

Software

Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.

Precisio Biotix Therapeutics Acquires CC Bio

March 1, 2024

Biotechnology

Precisio Biotix Therapeutics announced the acquisition of London-based CC Bio, the creator of the ZEUS antibacterial lysin design platform. The deal adds a complementary bioinformatics/endolysin capability and senior scientific talent to Precisio’s LysiThru discovery engine as the company expands its antibacterial therapeutics pipeline.

3E Acquires ChemChain

January 11, 2024

Cloud & SaaS

3E has acquired ChemChain, a Luxembourg-headquartered provider of blockchain-based digital product passport technology, to expand its Supply Chain & Sustainability offering and enhance the 3E Exchange platform. The acquisition brings ChemChain's proprietary IP and technology into 3E's compliance and digital product passport capabilities to accelerate supply chain transparency and sustainability solutions.

Edgewater Capital Partners Acquires GL CHEMTEC

August 11, 2022

Pharmaceuticals

Edgewater Capital Partners, a Cleveland-based lower middle-market private equity firm, has acquired GL CHEMTEC, a chemistry-based contract research organization (CRO) headquartered in Oakville, Ontario. Edgewater will support GLC's expansion of API development, scale-up and advanced materials capabilities to accelerate growth across North American pharma and life-sciences customers.

Limerston Capital Acquires Concept Life Sciences from Spectris plc

April 3, 2023

Biotechnology

Limerston Capital LLP has acquired Concept Life Sciences, a UK-based contract research organisation (CRO), in a carve-out from Spectris plc through its new fund Limerston Capital Partners II. The deal provides Concept Life Sciences with independent ownership, new leadership under CEO Dr Ben Cliff and additional investment to support growth across its drug discovery, development and API manufacturing services. Limerston intends to use the business as a platform for further buy-and-build and operational expansion in the life sciences sector.